JP2022550141A - 肺線維症モデルおよびそれを使用する方法 - Google Patents

肺線維症モデルおよびそれを使用する方法 Download PDF

Info

Publication number
JP2022550141A
JP2022550141A JP2022519551A JP2022519551A JP2022550141A JP 2022550141 A JP2022550141 A JP 2022550141A JP 2022519551 A JP2022519551 A JP 2022519551A JP 2022519551 A JP2022519551 A JP 2022519551A JP 2022550141 A JP2022550141 A JP 2022550141A
Authority
JP
Japan
Prior art keywords
cells
pats
alveolar
lung
aec1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022519551A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550141A5 (https=
Inventor
プルショタマ ラオ タタ，
アレクサンドラ タタ，
アルビンド コンキマラ，
芳彦 小林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2022550141A publication Critical patent/JP2022550141A/ja
Publication of JP2022550141A5 publication Critical patent/JP2022550141A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/42—Respiratory system, e.g. lungs, bronchi or lung cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/135—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/27—Lung cells, respiratory tract cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2503/00—Use of cells in diagnostics
    • C12N2503/04—Screening or testing on artificial tissues

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
JP2022519551A 2019-09-26 2020-09-28 肺線維症モデルおよびそれを使用する方法 Pending JP2022550141A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962906241P 2019-09-26 2019-09-26
US62/906,241 2019-09-26
US202062975294P 2020-02-12 2020-02-12
US62/975,294 2020-02-12
PCT/US2020/053164 WO2021062412A1 (en) 2019-09-26 2020-09-28 Lung fibrosis model and methods of using the same

Publications (2)

Publication Number Publication Date
JP2022550141A true JP2022550141A (ja) 2022-11-30
JP2022550141A5 JP2022550141A5 (https=) 2023-10-05

Family

ID=75166322

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519551A Pending JP2022550141A (ja) 2019-09-26 2020-09-28 肺線維症モデルおよびそれを使用する方法

Country Status (5)

Country Link
US (1) US12613236B2 (https=)
EP (1) EP4034142A4 (https=)
JP (1) JP2022550141A (https=)
CA (1) CA3156163A1 (https=)
WO (1) WO2021062412A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11739326B2 (en) 2017-11-14 2023-08-29 Massachusetts Eye And Ear Infirmary RUNX1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
CN115916218A (zh) * 2020-04-23 2023-04-04 斯格本斯眼科研究所有限公司 用于治疗纤维化的方法和材料
WO2023073738A1 (en) * 2021-10-29 2023-05-04 Universita' Degli Studi Di Trento Genetic construct for tracking and/or ablating quiescent cells
CN115772492B (zh) * 2023-02-13 2023-05-02 淇嘉科技(天津)有限公司 利用博来霉素体外构建肺纤维化疾病模型的方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016143803A1 (ja) * 2015-03-06 2016-09-15 国立大学法人京都大学 肺胞上皮細胞の分化誘導法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6962814B2 (ja) 2015-02-27 2021-11-05 ロート製薬株式会社 間葉系幹細胞培養用培地、間葉系幹細胞の培養方法及び間葉系幹細胞
US10975357B2 (en) 2017-06-27 2021-04-13 Trustees Of Boston University Methods and compositions related to differentiated lung cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016143803A1 (ja) * 2015-03-06 2016-09-15 国立大学法人京都大学 肺胞上皮細胞の分化誘導法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BARKAUSKAS, C. E. ET AL.: "Type 2 alveolar cells are stem cells in adult lung", J CLIN INVEST, vol. 123 (7), JPN6024040087, 2013, US, pages 3025 - 3036, ISSN: 0005429894 *
KOBAYASHI, Y. ET AL.: "Persistence of a regeneration-associated, transitional alveolar epithelial cell state in pulmonary f", BIORXIV, JPN6024040088, 25 November 2019 (2019-11-25), US, pages 093086228, ISSN: 0005556449 *
SUCRE, J. M. S. ET AL.: "Successful Establishment of Primary Type II Alveolar Epithelium with 3D Organotypic Coculture", AM J RESPIR CELL MOL BIOL, vol. 59 (2), JPN6024040089, 2018, US, pages 158 - 166, ISSN: 0005556448 *

Also Published As

Publication number Publication date
WO2021062412A1 (en) 2021-04-01
US20220341915A1 (en) 2022-10-27
EP4034142A1 (en) 2022-08-03
US12613236B2 (en) 2026-04-28
CA3156163A1 (en) 2021-04-01
EP4034142A4 (en) 2023-11-15

Similar Documents

Publication Publication Date Title
Kobayashi et al. Persistence of a regeneration-associated, transitional alveolar epithelial cell state in pulmonary fibrosis
Schneider et al. A novel P2X2‐dependent purinergic mechanism of enteric gliosis in intestinal inflammation
Guan et al. A human multi-lineage hepatic organoid model for liver fibrosis
Choi et al. Release of Notch activity coordinated by IL-1β signalling confers differentiation plasticity of airway progenitors via Fosl2 during alveolar regeneration
Strunz et al. Alveolar regeneration through a Krt8+ transitional stem cell state that persists in human lung fibrosis
Lynch et al. Submucosal gland myoepithelial cells are reserve stem cells that can regenerate mouse tracheal epithelium
Saraswati et al. Identification of a pro-angiogenic functional role for FSP1-positive fibroblast subtype in wound healing
US12613236B2 (en) Lung fibrosis model and methods of using the same
Hu et al. A Promising New Model: Establishment of Patient‐Derived Organoid Models Covering HPV‐Related Cervical Pre‐Cancerous Lesions and Their Cancers
Li et al. Human apical-out nasal organoids reveal an essential role of matrix metalloproteinases in airway epithelial differentiation
Pan et al. Generation of iPSC-derived human venous endothelial cells for the modeling of vascular malformations and drug discovery
Yeo et al. Chromatin accessibility dynamics of neurogenic niche cells reveal defects in neural stem cell adhesion and migration during aging
Kobayashi et al. Collagen type I-mediated mechanotransduction controls epithelial cell fate conversion during intestinal inflammation
Liu et al. Immunotherapy and senolytics in head and neck squamous cell carcinoma: phase 2 trial results
Xiao et al. Targeting Fibrotic Scarring by Mechanoregulation of Il11ra1+/Itga11+ Fibroblast Patterning Promotes Axon Growth after Spinal Cord Injury
JP2022550141A5 (https=)
Guan et al. CaMKK2 regulates macrophage polarization induced by matrix stiffness: implications for shaping the immune response in stiffened tissues
JP2022546253A (ja) 細胞外マトリクスの調節
Ng et al. Interleukin-11 causes alveolar type 2 cell dysfunction and prevents alveolar regeneration
Wang et al. EpCAM+ CD73+ mark epithelial progenitor cells in postnatal human lung and are associated with pathogenesis of pulmonary disease including lung adenocarcinoma
Yan et al. Targeting LOXL1-expressing hepatic stellate cell inhibits fibrogenesis and sinusoid angiogenesis via LOXL1/RUNX1/VEGFA axis during progression of liver fibrosis
Hoffman et al. Aberrant Transitional Alveolar Epithelial Cells Promote Pathogenic Activation of Lung Fibroblasts in Preclinical Fibrosis Modeling
US12268704B2 (en) Hippo regulation of cardiac vascularity, fibrosis, and inflammation
Nasir The integration of Tgfβ and Egfr signaling programs confers the ability to lead heterogeneous collective invasion
He et al. Stiffness regulates intestinal stem cell fate

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230927

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230927

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240830

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241003

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250324